Tumor Necrosis Factor Blocker [EPC]

971921 reported adverse events

Drugs of this class: ADALIMUMAB-BWWD ADALIMUMAB-ADAZ ADALIMUMAB-ATTO INFLIXIMAB ADALIMUMAB-AQVH GOLIMUMAB CERTOLIZUMAB PEGOL ETANERCEPT INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	115861
1	OFF LABEL USE	77034
2	ARTHRALGIA	66028
3	INJECTION SITE PAIN	60589
4	PAIN	60084
5	RHEUMATOID ARTHRITIS	59945
6	FATIGUE	47288
7	CONDITION AGGRAVATED	44759
8	INJECTION SITE ERYTHEMA	42325
9	HEADACHE	37524

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	INJECTION SITE RECALL REACTION	486	0.9662
1	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	5941	0.8935
2	RHEUMATOID FACTOR POSITIVE	4715	0.8588
3	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY	540	0.8477
4	SWOLLEN JOINT COUNT INCREASED	2367	0.8355
5	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1856	0.8205
6	RHEUMATIC FEVER	3261	0.8187
7	PEMPHIGUS	9224	0.7902
8	LUPUS VULGARIS	801	0.7868
9	C-REACTIVE PROTEIN ABNORMAL	4633	0.7693

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]